David Young, MD, Oncology, Rancho Mirage, CA, Eisenhower Health

DavidEugeneYoungMD

Oncology Rancho Mirage, CA

Hematologic Oncology

Physician

Dr. Young is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Young's full profile

Already have an account?

Education & Training

  • University of California Davis
    University of California DavisFellowship, Hematology/Oncology, 1988 - 1989
  • Harbor - UCLA Medical Center
    Harbor - UCLA Medical CenterFellowship, Medical Oncology, 1986 - 1988
  • San Joaquin General Hospital
    San Joaquin General HospitalResidency, Internal Medicine, 1980 - 1983
  • San Joaquin General Hospital
    San Joaquin General HospitalInternship, Transitional Year, 1979 - 1980
  • University of Illinois College of Medicine
    University of Illinois College of MedicineClass of 1979

Certifications & Licensure

  • AR State Medical License
    AR State Medical License 1999 - 2001
  • TN State Medical License
    TN State Medical License 1998 - 2001
  • CO State Medical License
    CO State Medical License 1983 - 1987
  • CA State Medical License
    CA State Medical License 1980 - 2022
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2014

Clinical Trials

Publications & Presentations

Abstracts/Posters

  • Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
    David E. Young, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • Processa Pharmaceuticals Entered into a Contingent Precedent in-Licensing Agreement with Elion Oncology for the Development of Eniluracil (pcs6422) for the Treatment of Advanced Gastrointestinal...
    Processa Pharmaceuticals Entered into a Contingent Precedent in-Licensing Agreement with Elion Oncology for the Development of Eniluracil (pcs6422) for the Treatment of Advanced Gastrointestinal...August 28th, 2020

Hospital Affiliations